BioAxone BioSciences, Inc. is a Cambridge-based biopharmaceutical company dedicated to developing innovative drug candidates for individuals suffering from neurotrauma and neurovascular disorders. Their groundbreaking research focuses on the creation of orally available inhibitors, such as NRL-1049 and BA-210, which have shown promising results in treating conditions like cerebral cavernous malformation and spinal cord injury.
With a strong commitment to reducing disability and transforming the lives of patients, BioAxone BioSciences is at the forefront of advancing medical solutions that target axon regeneration and blood-brain barrier dysfunction. Through strategic partnerships and ongoing clinical trials, they aim to bring their cutting-edge therapies to those in need, offering hope and potential breakthroughs in the field of neurology.
Generated from the website